New targeted treatment for ovarian cancer
Novel targeted therapy for treating Ovarian Cancer
This study is working on a new treatment for ovarian cancer that could help patients who struggle with the usual therapies, by using a special drug called EC359 to target the cancer cells more effectively and hopefully improve their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10893972 on NIH RePORTER |
What this research studies
This research aims to develop a novel targeted therapy for ovarian cancer, which is known for its high recurrence rates and resistance to standard treatments. The approach involves creating a small molecule inhibitor, EC359, that targets specific proteins involved in cancer cell survival and growth. By collaborating with a biotech company, the research team will synthesize this inhibitor and test its effectiveness in promoting cancer cell death and reducing cancer stem cells. Patients may benefit from a more effective treatment option that addresses the challenges of chemotherapy resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer, particularly those who have experienced recurrence or resistance to standard therapies.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with ovarian cancer, potentially improving survival rates.
How similar studies have performed: Other research has shown promise in developing targeted therapies for cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Vadlamudi, Ratna K — University of Texas Hlth Science Center
- Study coordinator: Vadlamudi, Ratna K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.